Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs Medtronic PLC (MDT) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
Medtronic PLCTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs Medtronic PLC — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.83, while Medtronic PLC trades at $90.02 (market cap $116.07B). The key difference: Medtronic PLC pays a 3.18% dividend while Rex Fang & Innovation Equity Premium Income ETF pays none, and Medtronic PLC is trading nearer its 52-week high, Rex Fang & Innovation Equity Premium Income ETF nearer its low. Which is the better fit depends on your goals.

FEPIMDT
Sector
Income / Options OverlayHealth
52-Week High
$49.54$105.35
52-Week Low
$37.98$73.75
Market Cap
$116.07B
Enterprise Value
$134.82B
Dividend Yield
3.18%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI, the REX FANG & Innovation Equity Premium Income ETF, trades at $41.88, showing minimal daily movement with a 0.02% gain. The technical outlook is bullish based on moving averages, though oscillators are neutral. The ETF employs a covered call strategy on a concentrated basket of AI and mega-cap tech stocks, generating a high yield through weekly dividends, with recent payouts around $0.20-$0.21 per share. Recent news highlights its transition to weekly distributions and investor interest due to its aggressive income approach.

FEPI offers a high-yield opportunity through its covered call strategy, appealing for income-focused investors, but faces risks from NAV erosion in downturns and limited upside potential. The concentrated portfolio of volatile tech names increases exposure to sector-specific swings, requiring careful risk assessment for long-term holdings.

Medtronic PLC

Medtronic (MDT) trades at $89.41, up 2.58% on the day, reflecting positive momentum. The stock exhibits bullish technical signals with strong moving average support and a consensus analyst price target of $98.75. Fundamentally, the company reported revenue of $33.54B for 2025 with a net income margin of 13.2%, and has consistently beaten EPS estimates in recent quarters. Recent news highlights institutional acquisitions and positive developments in medical technology platforms.

The outlook for MDT is positive, driven by earnings beats, robust cash flow, and growth in cardiac and robotic surgery segments. Key opportunities include undervaluation relative to analyst targets and dividend stability. Risks involve rising debt levels and competitive pressures in the medtech sector. The stock presents a compelling case for growth-oriented income investors.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About Medtronic PLC

One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.

Read more on MDT